论文部分内容阅读
目的探讨SMTNL2基因在肾癌组织及肾癌细胞系中的表达特征和临床意义。方法采用RT-PCR方法检测SMTNL2 m RNA在肾癌患者肿瘤组织及配对癌旁正常组织的表达及在5种肾癌细胞系(ACHN、Caki、769-P、786-O、293)中的表达,实时荧光定量PCR方法检测SMTNL2 m RNA在36例肾癌组织及配对癌旁正常组织中的表达水平,Western blot和免疫组化方法检测SMTNL2蛋白在36例肾癌组织及配对癌旁正常组织中的表达水平,分析SMTNL2基因在肾癌组织中的表达特征和临床病理参数的相关性。结果 SMTNL2 m RNA在肾癌组织中的表达水平显著低于癌旁正常肾组织(0.089±0.135 vs.0.325±0.165,P<0.05),SMTNL2 m RNA在肾癌细胞系(ACHN、Caki、769-P、786-O、293)中同样表现为低表达或无表达。SMTNL2在肾癌组织中的阳性蛋白表达率明显低于癌旁正常组织(13.9%vs.77.8%,P=0.021)。SMTNL2在肾癌组织中的SMTNL2阳性蛋白表达率与患者的性别(P=0.659)、年龄(P=0.462)、病理分级(P=0.391)和分期(P=0.696)无相关性。结论 SMTNL2基因在肾癌组织及肾癌细胞系中低表达,可能与肾癌的发生和进展有关。
Objective To investigate the expression and clinical significance of SMTNL2 gene in renal cell carcinoma and renal cell carcinoma cell lines. Methods The expression of SMTNL2 mRNA was detected by RT-PCR in tumor tissues and adjacent normal tissues of renal cell carcinoma (RCC) and the expression of SMTNL2 mRNA in five renal cancer cell lines (ACHN, Caki, 769-P, 786-O, 293) The expression of SMTNL2 mRNA was detected by real-time fluorescence quantitative PCR in 36 cases of renal cell carcinoma and adjacent normal tissues. Western blot and immunohistochemistry were used to detect the expression of SMTNL2 protein in 36 cases of renal cell carcinoma and adjacent normal tissues The expression of SMTNL2 gene in renal cell carcinoma and its correlation with clinical pathological parameters were analyzed. Results The positive expression of SMTNL2 mRNA in renal cell carcinoma (0.089 ± 0.135 vs.0.325 ± 0.165, P <0.05) was significantly lower than that in adjacent normal renal tissues (P <0.05) P, 786-O, 293) also showed low or no expression. The positive rate of SMTNL2 in renal cell carcinoma tissues was significantly lower than that in adjacent normal tissues (13.9% vs 77.8%, P = 0.021). The positive rate of SMTNL2 protein in SMTNL2 was not correlated with the gender (P = 0.659), age (P = 0.462), pathological grade (P = 0.391) and stage (P = 0.696) Conclusion The low expression of SMTNL2 gene in renal cell carcinoma and renal cell carcinoma may be related to the occurrence and progression of renal cell carcinoma.